Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: Atomoxetine
Clinical Trial ID: NCT00216281
Mode of action: NE/5HT transporter inhibitor
Phase: POC Failed
Company:
Note: No effect on cognition or negative symptoms as add-on; slight improvement of extra-pyramidal symptoms

Useful Links:

Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry . 2009 Apr 1 ; 70(4):518-25. Abstract

Kratochvil CJ, Vaughan BS, Daughton JM, Mayfield-Jorgensen ML, Burke WJ. Atomoxetine in the treatment of attention deficit hyperactivity disorder. Expert Rev Neurother. 2004 Jul 1 ; 4(4):601-11. Abstract


November 23, 2014
SRF News
SRF Comments
Text Size
Reset Text Size
Share/Bookmark

See our latest webinar, Cognition and Treatment Resistance in Schizophrenia, held November 10, 2014.

See our last webinar, Research Domain Criteria (RDoC) Applied to Verbal Hallucinations, held May 28, 2014.

Check out our Schizophrenia Bulletin Forum Discussion: Prefrontal Inefficiency Is Associated With Polygenic Risk for Schizophrenia.
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright